Joe Palca

Joe Palca is a science correspondent for NPR. Since joining NPR in 1992, Palca has covered a range of science topics — everything from biomedical research to astronomy. He is currently focused on the eponymous series, "Joe's Big Idea." Stories in the series explore the minds and motivations of scientists and inventors.

Palca began his journalism career in television in 1982, working as a health producer for the CBS affiliate in Washington, DC. In 1986, he left television for a seven-year stint as a print journalist, first as the Washington news editor for Nature, and then as a senior correspondent for Science Magazine.

In October 2009, Palca took a six-month leave from NPR to become science writer in residence at the Huntington Library and The Huntington Library, Art Collections, and Botanical Gardens.

Palca has won numerous awards, including the National Academies Communications Award, the Science-in-Society Award of the National Association of Science Writers, the American Chemical Society James T. Grady-James H. Stack Award for Interpreting Chemistry for the Public, the American Association for the Advancement of Science Journalism Prize, and the Victor Cohn Prize for Excellence in Medical Writing.

With Flora Lichtman, Palca is the co-author of Annoying: The Science of What Bugs Us (Wiley, 2011).

He comes to journalism from a science background, having received a Ph.D. in psychology from the University of California at Santa Cruz where he worked on human sleep physiology.

Editor's note: The Environmental Protection Agency has approved the use of mosquitoes infected with Wolbachia bacteria as a "biopesticide" in 20 states and the District of Columbia. The bacteria keep mosquitoes from spreading diseases like dengue and Zika. Back in 2012, NPR's Joe Palca wrote about scientist Scott O'Neill's 20 years of struggle to make the idea of Wolbachia-infected mosquitoes work. Here is his story.

Scientists in California think they may have found a way to transplant insulin-producing cells into diabetic patients who lack those cells — and protect the little insulin-producers from immune rejection. Their system, one of several promising approaches under development, hasn't yet been tested in people. But if it works, it could make living with diabetes much less of a burden.

For now, patients with Type-1 diabetes have to regularly test their blood sugar levels, and inject themselves with insulin when it's needed.

Copyright 2017 NPR. To see more, visit http://www.npr.org/.

ROBERT SIEGEL, HOST:

After 13 years in orbit around Saturn, NASA's Cassini spacecraft is about to plunge itself into the planet's atmosphere and disintegrate. NASA decided to put an end to the mission on Friday because the probe is almost out of fuel.

Cassini has provided exquisite details about the second-largest planet in our solar system.

Sometimes the true value of an invention isn't obvious until people start using it.

Consider what happened to inventor Nate Ball and his powered ascender. About 15 years ago, Ball was an undergraduate at the Massachusetts Institute of Technology when the U.S. Army approached MIT with a request: Can somebody build a powered device that can pull somebody up a rope, like Batman does?

Pages